Linagliptin is a dipeptidyl peptidase-4 inhibitor that was approved in 2011 by the US Food and Drug Administration as a treatment adjunctive to diet and exercise for the improvement of glycemic control in adults with type 2 diabetes mellitus (T2DM).
Pharmacology, Toxicology and Pharmaceutical Science
15
10%
Nursing and Health Professions
14
9%
Chemistry
12
8%
Biochemistry, Genetics and Molecular Biology
5
3%
Other
18
12%
Unknown
49
32%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 June 2014.
All research outputs
#20,653,708
of 25,371,288 outputs
Outputs from Clinical Therapeutics
#2,628
of 3,850 outputs
Outputs of similar age
#135,177
of 172,671 outputs
Outputs of similar age from Clinical Therapeutics
#29
of 47 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,850 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 12th percentile – i.e., 12% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 172,671 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one is in the 2nd percentile – i.e., 2% of its contemporaries scored the same or lower than it.
